Thoratec Takes Steps Into PCI-Support Market With EU Roll-Out Of HeartMate PHP
This article was originally published in The Gray Sheet
Executive Summary
The company plans a targeted roll-out of its heart pump in select European markets following a CE mark for the device, indicated to help stabilize patients during high-risk percutaneous coronary interventions.
You may also be interested in...
Thoratec Set To Begin U.S. Trial Of Catheter Heart Pump To Assist PCI
FDA has conditionally approved a 425-patient trial, called SHIELD II, comparing Thoratec's HeartMate PHP to Abiomed's Impella 2.5. The company expects the study to begin in the third quarter.
Impella 2.5 PMA Gives Abiomed Big Growth Potential For High-Risk PCIs
The approval, the first for a percutaneous hemodynamic support device, frees Abiomed's hand to market the miniature blood pump to a relatively broad patient population, analysts note.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”